[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588329":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":15,"locations":24,"responsibleParty":45,"collaborators":7,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",null,[9,12],{"name":10,"affiliation":5,"role":11},"Ruiyan Zhang, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":5,"role":14},"Xiaoqun Wang, M.D., Ph.D.","STUDY_CHAIR",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Chendie Yang, M.D., Ph.D.","CONTACT","0086-21-64370045-671503","yangcd1029@163.com",{"name":13,"role":18,"phone":22,"phoneExt":7,"email":23},"0086-21-64370045-671605","wangxq@shsmu.edu.cn",[25],{"facility":26,"status":27,"city":28,"state":7,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","RECRUITING","Shanghai","200025","China","CN",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39,40,41,43],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},{"name":13,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":17,"role":42,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":44,"role":42,"phone":7,"phoneExt":7,"email":7},"Shuo Feng, M.D., Ph.D.",{"type":11,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"RUIYAN ZHANG","M.D., Ph.D., FACC, FESC","100588329","cardiometabolic-evaluation-registry-of-heart-failure-100588329",false,"NCT06939985","Cardiometabolic evalUation REgistry of Heart Failure","Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study","CURE-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Chronic HF (NYHA II\\~IV), including:\n\n   * HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%.\n   * HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \\>40%.\n   * HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\\~49%.\n   * HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and\u002For functional abnormalities consistent with the presence of LV diastolic dysfunction\u002Fraised LV filling pressures, including raised natriuretic peptide.\n\nExclusion Criteria:\n\n1. Estimated survival ≤ 1 year.\n2. Pregnant or lactation, or have the intention to give birth within one year.\n3. Poor compliance, unable to follow-up.\n4. Mental or physical status not allowing written informed consent.\n5. Unwillingness to give informed consent.","ALL","18 Years",{"count":59,"type":60},5000,"ESTIMATED","5 Years","OBSERVATIONAL","This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural\u002Ffunctional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \\[EAT\\], perivascular adipose tissue \\[PVAT\\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.",[65,66,67],"Heart Failure","Metabolic Cardiovascular Syndrome","Metabolic Diseases",[69,70,71,72,73,74],"heart failure","cardiometabolic risk factors","epicardial adipose tissue","cardiac remodeling","heart failure phenotypes","major adverse cardiovascular events","2025-04-18",{"date":77,"type":78},"2025-04-23","ACTUAL",{"date":80,"type":78},"2015-01-01",{"date":82,"type":60},"2030-05-31",{"name":5,"class":6},1]